Introduction {#s1}
============

The cancer promoting function of HLA-G, such as rendering comprehensive suppressive roles to various types of immune component cells and enhancing the proliferation and accumulation of immune regulatory cells have been extensively investigated ([@B1]). Different degree of aberrant ectopic expression of HLA-G in cancers has been frequently found in most of the cancers studied so far, and the conception that HLA-G expression plays critical basically and clinical parts in cancer biology or therapy was established ([@B2]).

Besides application of the clinical tumor lesions, the direct roles of HLA-G participating in cancer progression have been demonstrated in previous studies with murine models. Data obtained from xenotumor or syngeneic immunocompetent murine tumor model revealed that both HLA-G1 or HLA-G5 expression promoted tumor development by impairment of innate and adaptive immune responses but favoring the immune suppressive cells such as CD11b+Gr1+ myeloid-derived suppressor cells (MDSC) expansion ([@B3], [@B4]). Fortunately, these could be reversed with HLA-G and/or receptor blockade by certain antibodies. With an immunodeficient murine ovarian cancer xenotumor model, we found that HLA-G1 expressing ovarian cancer cells had stronger invasion and metastasis potential compared that with the HLA-G-negative parental cells ([@B5]). We also presented the underlying mechanisms of HLA-G in tumor progression not only related to the inhibition of NK lysis, but to the specific induction of matrix metalloproteinase-15 (MMP-15) expression ([@B6]). This finding was solidified by later studies that HLA-G5 could induce the expression and activity of MMP-2 and MMP-9 in trophoblastic cells, while knock-down the HLA-G experssion resulted in dramatically decreased expression of MMPs was also observed ([@B7], [@B8]).

It\'s well documented thus far, with the alternative splicing of the primary transcript of *HLA-G*, seven isoforms including four-membrane bound (HLA-G1, -G2,-G3, and -G4) and three soluble (HLA-G5, -G6, and -G7) molecules were validated. Each unique HLA-G isoform contains one to three extracellular globular domains encoded by exon 2 (α 1), exon 3 (α2) and exon 4 (α3) respectively, and presence or absence of residues encoded by intronic sequences (IMGT/HLA database). However, these seven isoforms all contain the extracellular α 1 domain ([@B9], [@B10]). Among these isoforms, HLA-G1 and soluble HLA-G5 molecule have been studied more extensively due to the commercially available antibodies. However, it\'s reasonable that other novel unrecognized HLA-G isoforms remains unveiled. Indeed, based on immunohistochemical and deep sequencing, an important study by Tronik-Le Roux et al. ([@B11]) recently revealed that unrecognized novel HLA-G isoforms such as isoforms without α1 domain were presented in renal cancer samples. The findings raises the questions whether these novel HLA-G proteins are of clinical significance.

In our study, mAbs 4H84 and 5A6G7 were used to analyze the HLA-G expression by immunohistochemistry in primary colorectal cancer (CRC) samples. The percentage of HLA-G expression in tumor cells by mAbs 4H84 and 5A6G7 were compared, and the difference of the HLA-G expression (~Δ~HLA-G) was obtained by the percentage of HLA-G expression detected with HLA-G mAb 4H84 subtracted that with mAb 5A6G7. ~Δ~HLA-G with negative (~Δ~HLA-G~neg~), comparable (~Δ~HLA-G~com~) and positive (~Δ~HLA-G~pos~) were observed. Our findings revealed that patients with ~Δ~HLA-G~neg~ had much better survival than patients with ~Δ~HLA-G~com~ and ~Δ~HLA-G~pos~, and the ~Δ~HLA-G could be an independent prognostic factor for CRC patients.

Materials and methods {#s2}
=====================

CRC patients
------------

A cohort of 379 consecutive primary CRC lesions were provided by Tissue Bank of Taizhou Hospital of Zhejiang Province (National human genetic resources platform of China YCZYPT\[2017\]02). Patients were diagnosed and treated at the department of Gastrointestinal Surgery in Taizhou Hospital of Zhejiang Province from November 2004 to September 2012.

The clinical stage including stage I (*n* = 86), II (*n* = 114), III (*n* = 169), and IV (*n* = 11) respectively, were classified according to the UICC and the AJCC 7th TNM staging system ([@B12]). Details of the clinical history of the patients was recorded and the last follow-up was performed at April,15th, 2014. During the period, 38 patients was lost follow-up in the cohort. Overall survival was calculated from the date of surgical operation to the event (patient death, *n* = 113) or censored (last follow-up, *n* = 228) with the median follow-up of 45.0 months. 113 cancer-related deaths was observed in 10 stage I, 26 stage II, 71 stage III and 6 stage IV CRC patients. Informed written consent was provided by all participated patients and the study protocol was approved by the institutional ethic review board, Taizhou Hospital of Zhejiang Province.

Immunohistochemistry and staining evaluation
--------------------------------------------

Immunohistochemistry analysis for HLA-G expression was performed for each case-matched serial section primary CRC lesions on 4-μm paraffin-embedded sections according to our previous study with the two anti-HLA-G murine monoclonal antibodies (mAb) 4H84 (1:500, Exbio, Prague, Czech Republic) and 5A6G7 (1:500, Exbio, Prague, Czech Republic), respectively ([@B13], [@B14]). mAb 4H84 (IgG1) was immunized with amino acids 61--83 in the HLA-G alpha 1 domain, which recognizes an epitope located in the α 1 domain in denatured heavy chain to all α 1 domain containing HLA-G isoforms such as HLA-G1\~HLA-G7. mAb 5A6G7 (IgG1) was immunized with C-terminal amino acid sequence (22-mer) of HLA-G5 and -G6 proteins coupled to ovalbumin, which recognizes HLA-G isoforms such as HLA-G5 and -G6 encoded by the retained intron 4 (IMGT/HLA database), but not cross react with the HLA-G1 isoform.

The percentage of HLA-G expression was evaluated by two reviewers who were blind to the patient clinicopathological information. The percentage of HLA-G positive tumor cells was based on the presence of HLA-G staining while irrespective the staining intensity. HLA-G positive CRC cells \>5% in a section was considered as positive ([@B15]).

Difference of the percentage of HLA-G positve tumor cells (~Δ~HLA-G) in the case-matched CRC samples was calculated by the percentage of HLA-G expression detected with mAb 4H84 subtracted that with mAb 5A6G7. According to the value of ~Δ~HLA-G, three groups were obtained as follows: ~Δ~HLA-G~neg~ (~Δ~HLA-G\> −5.0%), ~Δ~HLA-G~com~ (−5.0%≤~Δ~HLA-G≤5.0%), and ~Δ~HLA-G~pos~ (~Δ~HLA-G\>5.0%).

Statistical analysis
--------------------

Pearson chi-square test was used for categorical data analysis. Survival probability analysis were performed with Kaplan-Meier method and log-rank test. Cox proportional hazards model was used for multivariate analysis. *P* \< 0.05 (two-tailed) was considered as statistically significant. All statistical analysis was performed with the SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA).

Results {#s3}
=======

Expression of HLA-G probed with mAbs 4H84 and 5A6G7 in CRC
----------------------------------------------------------

The IHC immunostaining pattern with mAbs 4H84 and 5A6G7 was shown in Figure [1](#F1){ref-type="fig"}. In these case-matched serial section primary CRC lesions, positive HLA-G expression was observed in 70.7% (268/379) with mAb 4H84 and in 60.4% (219/379) with mAb 5A6G7 in CRC patients. The percentage of the HLA-G expression detected with both antibodies ranges from negative to 99%. Neither the HLA-G expression status detected with mAb 4H84, nor with mAb 5A6G7 was statistical significantly related to the clinicopathological parameters such as gender, age, TNM status and AJCC clinical disease stage of CRC patients (Table [1](#T1){ref-type="table"}).

![Representative immunohistochemistry analysis of HLA-G expression patterns in primary CRC serial section lesions with mAbs 4H84 and 5A6G7. **(A)** mAbs 4H84~neg~5A6G7~neg~; **(B)** mAbs 4H84~neg~ 5A6G7~pos~; **(C)** mAbs 4H84~pos~5A6G7~pos~; and **(D)** mAbs 4H84~pos~5A6G7~neg~. (400×).](fonc-08-00361-g0001){#F1}

###### 

HLA-G expression detected with mAbs 4H84 and 5A6G7 related to the clinical parameters in CRC patients.

  **Variables**           **Cases**   **HLA-G (mAb 4H84)**                 **HLA-G(mAb 5A6G7)**                       
  ----------------------- ----------- ---------------------- ------------- ---------------------- ----- ------------- -------
  Gender                                                                                                              
      Male                214         69                     145 (67.8%)   0.150                  95    119 (55.6%)   0.329
      Female              165         42                     123 (74.5%)                          65    100 (60.6%)   
  Age                                                                                                                 
       ≤ median (66 ys)   188         52                     136 (72.3%)   0.490                  78    110 (58.5%)   0.776
      \>median            191         59                     132 (69.1%)                          82    109 (57.1%)   
  TNM stage                                                                                                           
      Tumor status                                                                                                    
      T~1+2~              108         26                     82 (75.9%)    0.016                  39    69 (63.9%)    0.110
      T~3~                256         79                     177 (69.1%)                          117   139 (54.3%)   
      T~4~                15          6                      9 (60.0%)                            4     11 (73.3%)    
      Nodal status                                                                                                    
      N~0~                201         57                     144 (71.6%)   0.870                  82    119 (59.2%)   0.421
      N~1~                109         34                     75 (68.8%)                           44    65 (54.3%)    
      N~2~                69          20                     49 (71.0%)                           34    35 (73.3%)    
      Metastasis status                                                                                               
      M~0~                368         110                    258 (70.1%)   0.135                  156   212 (57.6%)   0.690
      M~1~                11          1                      10 (90.9%)                           4     7 (63.6%)     
  Disease stage                                                                                                       
      I                   85          23                     62 (72.9%)    0.434                  28    57 (67.1%)    0.207
      II                  114         34                     80 (70.2%)                           54    60 (52.6%)    
      III                 169         53                     116 (68.6%)                          74    95 (56.2%)    
      IV                  11          1                      10 (90.9%)                           4     7 (63.6%)     

*Comparison of HLA-G expression status between or among each variable using the Pearson chi-square test. TNM, lymph-node-metastasis and stage according to the TNM classification*.

Be noted, differential HLA-G expression was commonly observed in the case-matched CRC samples between the samples detected with mAbs 4H84 and 5A6G7. In this CRC cohort, ~Δ~HLA-G~neg~ in 64 (16.9%), ~Δ~HLA-G~com~ in 159 (42.0%), and ~Δ~HLA-G~pos~ in 156 (41.2%) CRC cases was observed. Among the ~Δ~HLA-G~neg~ group, unexpected immunostaining was observed in 44 (11.6%) case-matched CRC lesions that no staining was detected with the mAbs 4H84 but with the 5A6G7 (mAbs 4H84^neg^5A6G7^pos^). The data were unpredictable beacuse all seven known α1 domain containing HLA-G isoforms could be recognized by the mAb 4H84. However, both ~Δ~HLA-G and its subgroups mAbs 4H84^neg^5A6G7^pos^ and 4H84 ^pos^5A6G7 ^neg^ status was unrelated to the clinicopathological parameters of CRC patients (Table [2](#T2){ref-type="table"}).

###### 

Difference (~Δ~HLA-G) with mAbs 4H84 and 5A6G7 related to the clinical parameters in CRC patients.

  **Variables**           **Cases**   ~**Δ**~**HLA-G**[^\*^](#TN2){ref-type="table-fn"}         **HLA-G (mAb 4H84 vs. 5A6G7)**                           
  ----------------------- ----------- --------------------------------------------------- ----- -------------------------------- ------- ----- ---- ---- -------
  Total                   379         64                                                  159   156                                      137   44   93   
  Gender                                                                                                                                                 
      Male                214         35                                                  96    83                               0.418   76    25   51   0.828
      Female              165         29                                                  63    73                                       61    19   42   
  Age                                                                                                                                                    
       ≤ median (66 ys)   188         32                                                  79    77                               0.996   68    21   47   0.759
      \>median            191         32                                                  80    79                                       69    23   46   
  TNM stage                                                                                                                                              
      Tumor status                                                                                                                                       
      T~1+2~              108         19                                                  47    42                               0.821   33    10   23   0.175
      T~3~                256         41                                                  107   108                                      100   31   69   
      T~4~                15          4                                                   5     6                                        4     3    1    
      Nodal status                                                                                                                                       
      N~0~                201         33                                                  88    80                               0.634   65    20   45   0.356
      N~1~                109         22                                                  40    47                                       46    18   28   
      N~2~                69          9                                                   31    29                                       26    6    20   
      Metastasis                                                                                                                                         
      M~0~                368         63                                                  154   151                              0.782   134   44   90   0.228
      M~1~                11          1                                                   5     5                                        3     0    3    
  Disease stage                                                                                                                                          
      I                   85          14                                                  41    30                               0.885   23    9    14   0.417
      II                  114         19                                                  47    48                                       42    11   31   
      III                 169         30                                                  66    73                                       69    24   45   
      IV                  11          1                                                   5     5                                        3     0    3    

~Δ~HLA-G: the difference of the percentage of HLA-G expression detected with mAb 4H84 subtracted that with mAb 5A6G7. ~Δ~HLA-G~neg:Δ~HLA-G \>−5.0%; ~Δ~HLA-G~com~:−5.0%≤~Δ~HLA-G≤5.0%; ~Δ~HLA-G~pos~: ~Δ~HLA-G \> 5.0%.

*Comparison of HLA-G expression status between or among each variable using the Pearson chi-square test. TNM, lymph-node-metastasis and stage according to the TNM classification*.

The mAb 5A6G7 specifically recognize an epitope located in the C-terminal amino acid sequence of HLA-G isoforms such as HLA-G5 and -G6. However, being with the α 1 domain, HLA-G5 and -G6 could also be recognized by the mAb 4H84. Therefore, to our prevailing knowledge, absence of mAb 4H84 labeling generally considered as the lack of HLA-G antigen expression. Noteworthy, the unexpected immunostaining pattern mAbs 4H84^neg^5A6G7^pos^ now sounds reasonable by the recent findings by the study Tronik-Le Roux et al. ([@B11]) that novel HLA-G isoforms lacks the α1 domain indeed exist in renal cancers.

Significance of the ~Δ~HLA-G status to CRC patient survival
-----------------------------------------------------------

Herein, Log-rank Mantel-Cox analysis of ~Δ~HLA-G status and clinical parameters in CRC patient survival was evaluated. Data showed that, in addition to CRC patient tumor status, nodal status, metastasis status and AJCC clinical disease stage, both ~Δ~HLA-G and its subgroups mAbs 4H84^neg^5A6G7^pos^ and 4H84 ^pos^5A6G7 ^neg^ status were significantly related to survival (Table [3](#T3){ref-type="table"}).

###### 

Log-rank Mantel-Cox analysis of clinical parameters in survival in CRC patients.

  **Variables**                                      **No. total**   **No. events**   **Mean survival**   **95% CI**   ***p*-value**   
  -------------------------------------------------- --------------- ---------------- ------------------- ------------ --------------- ---------
  Sex                                                Male            192              65                  72.0         66.2--77.7      0.927
                                                     Female          147              48                  73.4         66.6--80.1      
  Age                                                ≤ 66 ys         164              55                  73.4         67.1--79.6      0.755
                                                     \> 66 ys        175              58                  71.6         65.4--77.8      
  Tumor status                                       T~1+2~          97               18                  84.5         77.4--91.6      0.001
                                                     T~3~            228              87                  67.6         62.1--73.1      
                                                     T~4~            14               8                   60.6         40.1--81.2      
  Nodal status                                       N~0~            176              37                  84.4         79.2--89.6      \<0.001
                                                     N~1~            101              44                  62.4         54.1--70.7      
                                                     N~2~            62               32                  53.6         42.3--65.0      
  Metastasis status                                  M~0~            328              107                 73.4         68.8--77.8      0.089
                                                     M~1~            11               6                   51.9         25.2--78.7      
  Clinical stage                                     I               76               10                  86.3         79.7--92.9      \<0.001
                                                     II              98               26                  80.4         73.2--87.7      
                                                     III             154              71                  58.7         51.8--65.7      
                                                     IV              11               6                   51.9         25.1--78.7      
  HLA-G (mAb 4H84)                                   Neg             98               29                  76.7         69.0--84.5      0.250
                                                     Pos             241              84                  70.7         65.4--76.0      
  HLA-G (mAb 5A6G7)                                  Neg             142              54                  69.5         62.9--76.2      0.268
                                                     Pos             197              59                  74.9         69.0--80.8      
  ~Δ~HLA-G status[^\*^](#TN4){ref-type="table-fn"}                                                                                     
                                                     ~Δ~HLA-G~neg~   57               10                  87.9         79.4--96.4      0.017
                                                     ~Δ~HLA-G~com~   143              48                  71.0         64.0--77.9      
                                                     ~Δ~HLA-G~pos~   139              55                  67.2         60.3--74.1      
  4H84^neg^5A6G7^pos^                                ~/~             40               8                   85.5         74.8--96.2      0.046
  4H84^pos^5A6G7^neg^                                ~/~             84               33                  68.1         59.2--77.0      

*~Δ~HLA-G: the difference of the percentage of HLA-G expression detected with mAb 4H84 subtracted that with mAb 5A6G7. ~Δ~HLA-G~neg:Δ~HLA-G \>−5.0%; ~Δ~HLA-G~com~:−5.0%≤~Δ~HLA-G≤5.0%; ~Δ~HLA-G~pos~: ~Δ~HLA-G \> 5.0%*.

In addition, HLA-G expression status detected by either mAbs 4H84 (*p* = 0.250, Figure [2A](#F2){ref-type="fig"}) or 5A6G7 (*p* = 0.268, Figure [2B](#F2){ref-type="fig"}) were not associated with CRC patient survival. However, in the whole CRC cohort, ~Δ~HLA-G status was dramatically relevant to the patient survival (*p* = 0.017, Figure [2C](#F2){ref-type="fig"}). The mean survival for ~Δ~HLA-G~neg~ was 87.9 months (*n* = 57; 95% CI: 79.4--96.4), ~Δ~HLA-G~com~ was 71.0 months (*n* = 143; 95% CI: 64.0--77.9), and ~Δ~HLA-G~pos~ was 67.2 months (*n* = 139; 95% CI: 60.3--74.1) respectively, where patients with ~Δ~HLA-G~neg~ had a better outcome than that of patients with ~Δ~HLA-G~com~ and ~Δ~HLA-G~pos~. Interestingly, when compared the survival between the patients with mAbs 4H84^neg^5A6G7^pos^ (*n* = 40) and mAbs 4H84 ^pos^5A6G7^neg^ (*n* = 84), we found that patients with mAbs 4H84^neg^5A6G7^pos^ had a better survival than that of patients with mAbs 4H84^pos^5A6G7^neg^ (*p* = 0.046, Figure [2D](#F2){ref-type="fig"}). The mean survival for mAbs 4H84^neg^5A6G7^pos^ was 85.5 months (95% CI: 74.8--96.2), and mAbs 4H84^pos^5A6G7^neg^ was 68.1 months (95% CI: 59.2--77.0), respectively.

![Kaplan-Meier survival analysis of HLA-G expression status with mAbs 4H84 or 5A6G7 in CRC patients. **(A)** Comparison between HLA-G~neg~ and HLA-G~pos~ with mAb 4H84 in the whole cohort of CRC patients (*p* = 0.250); **(B)** between HLA-G~neg~ and HLA-G~pos~ with mAb 5A6G7 in the whole cohort of CRC patients (*p* = 0.268); **(C)** among patient with ~Δ~HLA-G~neg~, ~Δ~HLA-G~com~ and ~Δ~HLA-G~pos~ (*p* = 0.017) in the whole cohort of CRC patients. **(D)** between patients with HLA-G status of mAbs 5A6G7^pos^4H84^neg^ and with mAbs 5A6G7^neg^4H84^pos^ (*p* = 0.046); **(E)** among AJCC stage II CRC patient with ~Δ~HLA-G~neg~, ~Δ~HLA-G~com~ and ~Δ~HLA-G~pos~ (*p* = 0.031); and **(F)** among AJCC stage III CRC patient with ~Δ~HLA-G~neg~, ~Δ~HLA-G~com~ and ~Δ~HLA-G~pos~ (*p* = 0.158). Note: *p*-value in double-head arrow represents the comparison between subgroups of the CRC patients indicated.](fonc-08-00361-g0002){#F2}

To mitigate the heterogeneity of the samples on the prognistic value of ~Δ~HLA-G, we futher analyzed the relevance of ~Δ~HLA-G status to survival for patients with particular AJCC stages. The survival analysis was performed for patients with AJCC stage II and III, because limited evens were occurred in patietns with AJCC stage I (N~event~ = 10) and stage IV (N~event~ = 6). Data showed that, among patients with AJCC stage II, ~Δ~HLA-G status was also obivously associated with the patient survival, the mean survival for ~Δ~HLA-G~neg~ (*n* = 17)~,\ Δ~HLA-G~com~ (*n* = 39), and ~Δ~HLA-G~pos~ (*n* = 42) was 99.3, 79.1, and 70.5 months, respectively (*p* = 0.031). For the subgroups of stage II patients, significant difference for survival was also observed between the patients with ~Δ~HLA-G~neg~ vs. ~Δ~HLA-G~pos~ (*p* = 0.012; Figure [2E](#F2){ref-type="fig"}). Among patients with AJCC stage III, though does not reach the statistical significance, the mean survival for ~Δ~HLA-G~neg~ (*n* = 27, 72.7 months) was much longer than patients with~,\ Δ~HLA-G~com~ (*n* = 62, 53.6 months) and ~Δ~HLA-G~pos~ (*n* = 65, 56.7 months; *p* = 0.158, Figure [2F](#F2){ref-type="fig"}).

Value of ~Δ~HLA-G status on prognosis for CRC patients
------------------------------------------------------

Finally, the prognostic value of the ~Δ~HLA-G combined with CRC patient clinical parameters was analyzed (Table [4](#T4){ref-type="table"}). By univariate analysis, primary tumor burden (T~3+4~ vs. T~1+2~, *HR* = 2.504, *p* \< 0.001), regional lymph node (N~1+2~ vs. N~0~, *HR* = 3.064, *p* \< 0.001), distant metastases (M~1~ vs. M~0~, *HR* = 2.009, *p* = 0.097), and clinical disease stage (III + IV vs. I + II, *HR* = 3.142, *p* \< 0.001) was markedly associated with worse prognosis; However, ~Δ~HLA-G ~neg~ (~Δ~HLA-G ~neg~ vs. ~Δ~HLA-G ~com+pos~, *HR* = 0.414, *p* = 0.008) was obviously associated with a better prognosis. Furthermore, by multivariate analysis, data showed that primary tumor (*p* = 0.030) and ~Δ~HLA-G status (*p* = 0.008) remain statistic significantly, indicating that ~Δ~HLA-G status could be an independent prognostic factor for CRC patients.

###### 

Cox proportional hazards model analysis of multi-variables in survival for CRC patients.

  **Variables**                                      **Categories**                          **Univariate analysis**   **Multivariate analysis**                          
  -------------------------------------------------- --------------------------------------- ------------------------- --------------------------- ---------------------- -------
  Sex                                                Male vs. Female                         0.983 (0.667--1.427)      0.927                                              
  Age (years)                                        \>66 vs. ≤ 66                           1.060 (0.733--1.534)      0.756                                              
  Tumor status                                       T~3+4~ vs. T~1+2~                       2.504 (1.512--4.147)      \<0.001                     1.793 (1.059--3.035)   0.030
  Nodal status                                       N~1+2~ vs. N~0~                         3.064 (2.062--4.554)      \<0.001                     0.919 (0.107--7.921)   0.919
  Metastasis status                                  M~1~ vs.M~0~                            2.009 (0.881--4.580)      0.097                       1.047 (0.419--2.612)   0.922
  Clinical stage                                     III+IV vs. I+II                         3.142 (2.108--4.683)      \<0.001                     2.913 (0.322--26.34)   0.341
  HLA-G (mAb 4H84)                                   Pos vs. Neg                             1.267 (0.830--1.933)      0.272                                              
  HLA-G (mAb 5A6G7)                                  Pos vs. Neg                             0.812 (0.561--1.175)      0.270                                              
  ~Δ~HLA-G status[^\*^](#TN5){ref-type="table-fn"}   ~Δ~HLA-G ~neg~ vs. ~Δ~HLA-G ~com+pos~   0.414 (0.216--0.792)      0.008                       0.416 (0.217--0.798)   0.008

HR, hazard ratio; 95% CI = 95% confidence interval.

*~Δ~HLA-G: the difference of the percentage of HLA-G expression detected with mAb 4H84 subtracted that with mAb 5A6G7. ~Δ~HLA-G~neg:Δ~HLA-G \> −5.0%; ~Δ~HLA-G~com~: −5.0%≤~Δ~HLA-G≤5.0%; ~Δ~HLA-G~pos~: ~Δ~HLA-G \> 5.0%*.

Discussion {#s4}
==========

Since HLA-G was firstly found in cytotrophoblast in 1990 ([@B16]), immune regulation functions of HLA-G have been investigated extensively, and important roles of HLA-G in the maintenance for the fetal-maternal immunotolerance were established ([@B17]). However, with the HLA-G expression was observed in cancers for the first time in 1998, numerous studies have been carried out focusing on the basic biology and clinical significance of HLA-G in malignancies ([@B2], [@B18]). In clinical settings and pre-clinical murine models, HLA-G expression was strongly related to the capability of tumor cell invasiveness and metastasis, to advanced disease stage and poor survival in cancer patients ([@B1], [@B13]). Thus far, the importance of HLA-G in cancer promotion and progression has been widely acknowledged. Consequently, HLA-G as cancer immunotherapy target was proposed.

One of the distinct features of *HLA-G* is that, by gene alternative splicing, its primary transcript could generate at least seven isoforms (HLA-G1\~HLA-G7) ([@B9]). However, it\'s reasonable more novel unrecognized HLA-G isoforms remains unveiled because different reading frame could be formed by the gene splicing. This is indeed in case of HLA-G as reported in a recent study ([@B11]). In that study, HLA-G expression in renal cancer lesions (RCC) was evaluated by immunohistochemistry (IHC) with different HLA-G antibodies including mAbs 4H84 and 5A6G7. Unexpectedly, in some RCC cases, IHC results showed that no immunostaining was detected with the mAb 4H84 but strongly with mAb 5A6G7 (mAbs 4H84^neg^5A6G7^pos^). The staining pattern seems controversy to our prevailing knowledge that absence of mAb 4H84 labeling generally accounts for the lack of HLA-G expression. This is based on the fact that all previously identified seven HLA-G isoforms contains α 1 domain and could be detected by the mAb 4H84.

In this context, we presented similar puzzled data of staining pattern (mAbs 4H84^neg^5A6G7^pos^) on the case-matched lung and ovarian cancers and lead to hot discussion by the participants during the 7th international conference on HLA-G (Paris, 2015. <http://www.hlag2015.sitew.fr/#Program.C>). Noteworthy, now the unpredictable and unexpected immunostaining pattern could be explained by the findings revealed by Tronik-Le Roux et al. ([@B11]), that unrecognized HLA-G isoforms heretofore such as α1 domain-absent isoforms were presented in CRC samples. The very instructive findings raises the questions whether these novel HLA-G proteins are of clinical significance because similar, distinct or opposing functions was observed among different isoforms.

Substantial previous evidence has proved that HLA-G is a crucial tumor-driven immune escape factor involved in alterating the anti-tumor responses of immune contexture of solid tumors like CRC, and thus in determination of the fate of tumor development and patient clinical outcome ([@B1]). Through binding to the immune inhibitory receptors (particularly ILT2 and/or ILT4) expressed on various immune cells, HLA-G could directly or indirectly impair anti-tumor immune responses ([@B2]). Accumulating data revealed that HLA-G has comprehensive immune suppressive functions to T cells, B cells, NK cells and DCs, and to enhance the generation of immune regulatory cells such as MDSCs, DC-10 and M2-macrophages ([@B19]--[@B23]). Among HLA-G isofroms, the immune suppression mediated by HLA-G1 and HLA-G5 isoforms was well documented by different research groups, including ours. We found that HLA-G1 expressed in ovarian cancer cell lines NIH:OVCAR-3 and HO-8910 ([@B6], [@B24]), hepatocellular carcinoma cell line Hep G2 ([@B25]), lung adenocarcinoma cell line A549 ([@B26]) could dramatically decrease the NK cell cytolysis. We also found that by blocking the HLA-G with mAb 87G or its receptor ILT2 expressed on the effector NK-92 cell line could significantly reverse the NK cell lysis function ([@B24], [@B26]). Furthermore, HLA-G1 and HLA-G5 isoforms in NK cell cytolysis suppression is dependent on the level of both HLA-G1 and HLA-G5 expression. Compared to HLA-G1, HLA-G5 has a more potent inhibition effect on the NK cytolysis. Moreover, HLA-G1 and HLA-G5 isoforms have an additive effect on NK cytolysis suppression ([@B27], [@B28]). HLA-G1/ILT2 engagement on T cells could result in inhibition of CD4+ T cell alloproliferation and CD8+ and Vγ9Vδ2 T cell cytolysis and IFN-γ production ([@B29]--[@B31]). HLA-G5/ILT2 mediated signal was observed to supress B cell immunoglobulin production, and HLA-G5/ILT4 interaction impair phagocytosis and reactive oxygen species production of neutrophils ([@B32], [@B33]). Other functions such as impairment of the expression and function of chemokine receptors in T cells, NK cells and B cells mediated by HLA-G5/ILT2 signaling pathway was also reported ([@B34]).

As expected that, like other HLA antigens, subtle structural alterations in HLA-G molecules can have dramatic effects on innate and adaptive immune modulation, and consequently, related to different clinical significance ([@B35], [@B36]). In this scenario, recent studies revealed that the nature of the bound peptide could influence the substructure and stability of HLA-G, and a single amino acid exchange in the α2 domain in allelic HLA-G subtypes of *HLA-G*^\*^01:01 and *HLA-G*^\*^01:04 has obivously different capability in NK cell lysis inhibition ([@B36], [@B37]). HLA-G3 was found less efficient than HLA-G1 at inducing HLA-E surface expression ([@B38]). Moreover, unlike HLA-G1, HLA-G3 could not inhibit human monocyte/macrophage-mediated swine endothelial cell lysis or NK cells against K562 cells ([@B39], [@B40]). These findings indicated that distinct structure of HLA-G molecules or isoforms features with unique biological functions and could impact on its recognition by receptors of both innate and adaptive immune systems.

To evaluate whether different structural HLA-G molecaules have different clinical relavence, in this study, HLA-G expression in 379 case-matched primary CRC lesions were analyzed by IHC with mAb 4H84 and mAb 5A6G7. Different percentage of HLA-G expression was commonly observed between the case-matched serial sections when using the mAb 4H84 and mAb 5A6G7. Furthermore, clinical relevance of the difference of HLA-G expression (~Δ~HLA-G) between mAbs 4H84 and 5A6G7 was evaluated. Our data revealed that lower percentage of HLA-G expression detected with mAb 4H84 than mAb 5A6G7 (~Δ~HLA-G~neg~) was found in 16.9% (64/379), comparable percentage detected with both antibodies (~Δ~HLA-G~com~) was found in 42.0% (159/379), higher percentage of HLA-G expression detected with mAb 4H84 than mAb 5A6G7 (~Δ~HLA-G~pos~) was found in 41.2% (156/379) of CRC samples, respectively. Patients with ~Δ~HLA-G~neg~ had significantly better survival than those with ~Δ~HLA-G~com~ and ~Δ~HLA-G~pos~ CRC patients (*p* = 0.017). A better predictive value of ~Δ~HLA-G~neg~ was also observed for patients with either AJCC stage II or III. Moreover, patients with staining pattern 4H84^neg^5A6G7^pos^ had a better survival than that of patients with 4H84^pos^5A6G7^neg^ (*p* = 0.046). Multivariate analysis by Cox proportional hazards model also showed that ~Δ~HLA-G could be an independent prognostic factor for CRC patients (*p* = 0.008).

Different clinical significance of HLA-G expression in cancers detected with mAb 4H84 and mAb 5A6G7 was also reported in previous studies. HLA-G expression detected with mAb 4H84 was found strongly relative to clinical stage and poor prognosis in lung cancers, while no such significance was observed for HLA-G5/-G6 detected with mAb 5A6G7 ([@B26], [@B41]). Unlike detected with mAb 4H84, HLA-G expression detected with mAb 5A6G7 was also found to unrelated to clinical parameters such as FIGO stage and prognosis in ovarian cancers ([@B14], [@B42]). Thus, the immunostaining pattern for HLA-G expression with 4H84^neg^5A6G7^pos^ strengthen the existence of novel α1 domain-absent HLA-G isoforms which could not be probed by the mAb 4H84. However, their specific function in physiological and pathological conditions still remains to be determined. To this end, being lack of currently available commercial antibodies for those novel HLA-G isoforms, a large campaign to develop new antibodies is extremely necessary and even inevitable.

Summary, our preliminary findings revealed that novel unidentified HLA-G isoforms recognized by mAbs 5A6G7 but not 4H84 might be existed in colorectal cancers. Moreover, HLA-G isoforms recognized by mAb 5A6G7 is of different clinical significant from that of the isoforms recognized by mAb 4H84. In the era of the precision medicine, the inter- and intra-tumor heterogeneity caused by complexity of the validated and even novel HLA-G isoforms, interpretation of the significance of HLA-G in cancers must be with extreme caution before their distinct roles are elucidated.
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